Study the Effect of Pulsed Dye Laser Versus Carboxytherapy in the Treatment of Striae Rubra

NCT ID: NCT06591208

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-11

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical intrapatient randomized trial will be conducted on 20 patients of both genders complaining from bilateral symmetrical striae rubra. They will be recruited from Outpatient Clinic of Dermatology Department of Cairo University Hospitals. All included patients will be subjected to:

1. Informed written consent will be taken from every patient including the study.
2. Detailed history including onset, course, duration of the disease and occupation, predisposing factors, associated diseases and previous treatments.
3. Outcome will be done at baseline, after the last session and 2 months after the last session:

* Photographing documentation: two photographs (in appropriate views) will be taken on two occasions; before each session (Baseline), and 2 months after the last treatment session.
* Modified Vancouver Scar Scale The modified Vancouver Scar Scale (mVSS 1) evaluates four indicators: vascularity, pigmentation, pliability and height It has a score ranging from 0-13 The modified Vancouver Scar Scale (mVSS 2) evaluates three indicators: vascularity, pliability and height It has a score ranging from 0-10
* Dermaspectrometer Dermaspectrometer will be measure erythema index at baseline, after the last session and 2 months after the last session.
* Histopathological Assessment Skin biopsies using 4 mm punch biopsies will be obtained from SR before treatment (baseline) and 2 months after the last treatment sessions. The post-treatment biopsy will be taken from the vicinity of the baseline biopsy. Tissues will be fixed in 10% buffered formalin, will be embedded in paraffin and will be sectioned into 5 µm-thick sections. Specimens will be stained with hematoxylin and eosin (H \& E) and/or Orcein (for demonstration of elastic fibers). Histological evaluations will be carried out under a light microscopy.

Pathologic assessment for the stria will be evaluated each of the epidermis, dermis, collagen fibers and elastic fibers. Degree of improvement will be assessed by examining the following criteria.

A.Epidermis: Epidermal thickness and presence of rete ridges B.Dermis: Papillary dermal edema, dermal vascularity, and presence of skin appendages.

C.Collagen fibers will be assessed for its thickness, commenting on whether it's fibrillar, fine thickness, normal thickness or sclerotic, besides the presence of perpendicular blood vessels towards the epidermis.

D.Elastic fibers: will be evaluated it through Orcein stain for its presence or absence, its thickness if present; fragmented or fibrillar.

\* Blinded investigator evaluation

Two independent blinded investigators will be assessed clinical improvement. Assessment of the standardized photographs using the following score:

-1 = worse, 0 = no change,

1. = weak (1-24% improvement in striae),
2. = moderate (25-49% improvement in striae),
3. = good (50-74%improvement in striae)
4. = excellent (75-100% improvement in striae)

* Patients' satisfaction

The patients' self-satisfaction for each modality of treatment (regarded improvement and side effects of each modality) measured on a five-point scale:

0 → not satisfied,

1. → moderately satisfied,
2. → satisfied, Treatment Protocol Twenty patients will be subjected to Pulsed Dye Laser (PDL) on one randomized side of their bodies and carboxytherapy on the other side for four sessions with four weeks' interval between sessions. Randomization will be done through picking red (PDL) yellow (carboxytherapy) cards.

After taking photographs, patients will be locally anesthetized by topical lidocaine under occlusion for 1 h on the side of carboxytherapy. The cream will be wiped off with a wet gauze when the session started. Protective eye wear will be provided to the patient, treating doctor and all the personnel assisting the procedure.

One randomized side of the affected area will be assigned to PDL (Cynosure - Chelmsford, MA-USA) with wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm according to the width of the striae.

The other side will be assigned to carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that will be automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently will be adjusted to a flow rate of 1 cc/sec. The injection will be performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point.

Each patient will be received 4 sessions with 4 weeks' intervals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Striae Distensae

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single group 20 patients subjected PDL on one randomized side and carboxytherapy on the other side

Group Type OTHER

pulsed dye laser

Intervention Type DEVICE

PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm

Carboxytherapy

Intervention Type DEVICE

carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic "popcorn appearance".

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pulsed dye laser

PDL (Cynosure - Chelmsford, MA-USA) wavelength 585 nm at a fluence 2.5-5 J/cm2, pulse duration of 0.5 ms and spot size 7 -10 mm

Intervention Type DEVICE

Carboxytherapy

carboxytherapy (Carbo - Programmable automatic carbon dioxide therapy apparatus, MA-USA) that was automatically calibrated to adjust the flow rate, through regulation of infusion pressure and the dosage of CO2 in ml. the infusion velocity consequently was adjusted to a flow rate of 1 cc/. The injection performed slowly, subcutaneously, by tilting the needle at 15 degree using a sterile disposable insulin needle, with the depth adjusted at 2 mm. the gas volume per injection spot is 2ml with 1.5 cm spacing between each injection point. End point was skin distension with the gas giving the characteristic "popcorn appearance".

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Both genders are included. 2. Patients above 18 years old. 3. Patients have bilateral symmetrical striae rubra lesions.

Exclusion Criteria

1. Pregnancy
2. Scarring and keloid tendencies.
3. Active skin infection, active infection of herpes simplex virus.
4. Patient on Prior steroid therapy
5. Patient have History of Cushing syndrome
6. Patients with concomitant disease during the study (e.g., hepatic, renal, cardiac, autoimmune diseases, diabetes mellitus, and/or bleeding disorders).
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aya Mohamed Fahim

principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rana Fathy Helal, assistant professor

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Aya mohamed fahim, assistant professor

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rawan barakat Saleh, M.B.B.Ch.

Role: CONTACT

+20155-407-3917

References

Explore related publications, articles, or registry entries linked to this study.

Hodeib AA, Hassan GFR, Ragab MNM, Hasby EA. Clinical and immunohistochemical comparative study of the efficacy of carboxytherapy vs platelet-rich plasma in treatment of stretch marks. J Cosmet Dermatol. 2018 Dec;17(6):1008-1015. doi: 10.1111/jocd.12481. Epub 2018 Jan 7.

Reference Type BACKGROUND
PMID: 29316152 (View on PubMed)

Shokeir H, El Bedewi A, Sayed S, El Khalafawy G. Efficacy of pulsed dye laser versus intense pulsed light in the treatment of striae distensae. Dermatol Surg. 2014 Jun;40(6):632-40. doi: 10.1111/dsu.0000000000000007.

Reference Type BACKGROUND
PMID: 24852467 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

effect PDL vs carboxy on stria

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.